Published : 01 Jul 2026
CHICAGO, IL — July 1, 2026 — Aagami, Inc., a premier global life sciences consulting firm, is proud to announce a new client win. An innovative biopharmaceutical company specializing in recombinant protein and peptide therapeutics has appointed Aagami to support global licensing and strategic partnering initiatives for three of its highly promising clinical-stage biologic assets.
This mandate underscores Aagami’s continued success in identifying high-potential biotechnology innovations and matching them with global pharmaceutical markets to accelerate the development of life-saving treatments.
Under this agreement, Aagami will leverage its extensive global network to identify, negotiate, and secure licensing, co-development, or other strategic partnerships for the following therapeutic assets:
Long-Acting Biologic for Rare Metabolic Disease (Phenylketonuria - PKU): A novel, long-acting therapeutic enzyme designed to treat Phenylketonuria (PKU), a rare genetic metabolic disorder. Utilizing a proprietary long-acting PEGylation technology, this asset is engineered for lower immunogenicity and an extended half-life, offering a highly convenient and effective treatment option for PKU patients.
Amino-Acid Depletion Therapy for Malignant Solid Tumors: An innovative oncology asset based on metabolic "starvation" therapy. This arginine-degrading enzyme is designed to selectively exhaust arginine in the tumor microenvironment, effectively starving and controlling the growth of malignant solid tumors.
Third-Generation Biologic for Hematological Malignancies (ALL & LBL): A globally innovative recombinant enzyme targeted for the treatment of Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL). It has demonstrated highly stable pharmacokinetics and is designed to improve the safety and efficacy of combination chemotherapy regimens.
"We are thrilled to be selected by this pioneering innovator to represent these highly differentiated biological assets," said the leadership at Aagami, Inc. "Whether it is addressing the significant unmet needs in rare metabolic disorders like PKU or advancing novel starvation therapies for solid tumors, this pipeline represents the frontier of recombinant protein innovation. We look forward to securing the right strategic partners to bring these therapies to patients worldwide."
If you are interested in this partnering opportunity, please contact action@aagami.com
The client is a clinical-stage biopharmaceutical enterprise specializing in the independent research and development of genetically engineered recombinant protein and peptide drugs. Leveraging its proprietary long-acting drug design platforms, the company is dedicated to developing innovative therapeutic enzymes and biologics for oncology, metabolic diseases, and other severe medical conditions.
Aagami is a specialized global consulting firm that helps life sciences, biotechnology, and medical device companies achieve global growth. Through strategic partnering, technology licensing, and cross-border joint ventures, Aagami bridges the gap between innovative technologies and high-growth international healthcare markets.